HC Wainwright Reiterates Buy Rating for Evaxion Biotech A/S (NASDAQ:EVAX)

Evaxion Biotech A/S (NASDAQ:EVAX)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $14.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 453.36% from the company’s previous close.

Separately, Lake Street Capital dropped their price target on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th.

Evaxion Biotech A/S Trading Down 4.9 %

EVAX stock opened at $2.53 on Thursday. Evaxion Biotech A/S has a 1-year low of $2.22 and a 1-year high of $22.05. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. The company has a market capitalization of $2.97 million, a price-to-earnings ratio of -1.74 and a beta of -0.28. The business has a 50 day simple moving average of $3.65 and a two-hundred day simple moving average of $9.60.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC bought a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned about 2.98% of Evaxion Biotech A/S as of its most recent filing with the Securities and Exchange Commission. 11.04% of the stock is currently owned by hedge funds and other institutional investors.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.